Previous close | 0.1800 |
Open | 0.1850 |
Bid | 0.1950 x 102397000 |
Ask | 0.2000 x 716752400 |
Day's range | 0.1800 - 0.2050 |
52-week range | 0.1300 - 0.6250 |
Volume | |
Avg. volume | 22,601,570 |
Market cap | 1.144B |
Beta (5Y monthly) | 2.26 |
PE ratio (TTM) | N/A |
EPS (TTM) | -0.0050 |
Earnings date | 28 Aug 2022 - 01 Sept 2022 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 0.55 |
SYDNEY & LOS ANGELES, May 17, 2022--Imugene Limited and City of Hope's first patient was dosed in a clinical trial evaluating the safety of new cancer-killing virus CF33-hNIS VAXINIA.
New clinical trial supply agreement with MSD, a tradename of Merck & Co., Inc., Kenilworth, NJ., USA for Phase 2 clinical study (nextHERIZON) in HER-2 positive gastric or gastroesophageal junction adenocarcinomasnextHERIZON will assess HER-Vaxx in combination with chemotherapy or pembrolizumab in patients with HER-2 positive gastric cancer that have failed trastuzumab SYDNEY, Australia, March 14, 2022 (GLOBE NEWSWIRE) -- Imugene (ASX: IMU) today announced a new clinical trial collaboration and s
Just because a business does not make any money, does not mean that the stock will go down. Indeed, Imugene ( ASX:IMU...